TP53-mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Autor: Daver, NG, Maiti, A, Kadia, TM, Vyas, P, Majeti, R, Wei, AH, Garcia-Manero, G, Craddock, C, Sallman, DA, Kantarjian, HM

Publikováno v: Cancer Discov

TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML have lower response rates to either induction chemotherapy, hypomethylating agent�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c07190f2edf23ed9786d27222e9dbd
https://europepmc.org/articles/PMC9627130/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

What have we learned about TP53-mutated acute myeloid leukemia?

Autor: Shahzad M; Division of Hematology and Oncology, Moffitt Cancer Center, Tampa, FL, USA., Amin MK; Division of Hematologic Malignancies & Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah MV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hiwase D; Department of Hematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia., Arber DA; Department of Pathology, University of Chicago, Chicago, IL, USA., Kharfan-Dabaja MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA., Badar T; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA. badar.talha@mayo.edu.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Nov 19; Vol. 14 (1), pp. 202. Date of Electronic Publication: 2024 Nov 19.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.

Autor: DiNardo CD; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Verma D; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Baran N; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Section of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Bhagat TD; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Skwarska A; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Lodi A; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Saxena K; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cai T; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Su X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guerra VA; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Poigaialwar G; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Kuruvilla VM; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konoplev S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gordon-Mitchell S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Pradhan K; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Aluri S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Hackman GL; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Chaudhry S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Collins M; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Sweeney SR; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.; Institute for Cell and Molecular Biology, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA., Busquets J; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Rathore AS; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA., Deng Q; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green MR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grant S; Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA.; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA., Demo S; Calithera Biosciences, San Francisco, CA, USA., Choudhary GS; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Sahu S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Agarwal B; GenomeRxUS, Secane, PA, USA., Spodek M; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Thiruthuvanathan V; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Will B; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Steidl U; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Tippett GD; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burger J; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kornblau S; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver NG; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naqvi K; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tiziani S; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu.; Institute for Cell and Molecular Biology, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu.; Department of Oncology, Dell Medical School, Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu., Verma A; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. amit.verma@einsteinmed.edu., Konopleva M; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. marina.konopleva@einsteinmed.edu.; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. marina.konopleva@einsteinmed.edu.

Publikováno v: Nature cancer [Nat Cancer] 2024 Oct; Vol. 5 (10), pp. 1515-1533. Date of Electronic Publication: 2024 Sep 19.

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).

Autor: Aakash F; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas., Gisriel SD; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut., Bennett JM; James P. Wilmot Cancer Center, Division of Hematopathology, University of Rochester Medical Center, Rochester, New York., Bejar R; Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, California., Bewersdorf JP; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Borate UM; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Boultwood J; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Brunner AM; Division of Hematology, Massachusetts General Hospital Brigham, Boston, Massachusetts., Buckstein R; Division of Medical Oncology/Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Carraway HE; Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Churpek JE; Division of Haematology, Oncology, and Palliative Care, Department of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas., DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland., Efficace F; Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy., Fenaux P; Service d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris), Université de Paris-Cité, Paris, France., Figueroa ME; Biochemistry & Molecular Biology, Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine, Miami, Florida., Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas., Gore SD; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland., Greenberg PL; Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Halene S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut., Hourigan CS; Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia., Kim TK; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Kim N; NCI, NIH, Bethesda, Maryland., Komrokji RS; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Kutchroo VK; Brigham and Women's Hospital, Boston, Massachusetts., List AF; Chief Scientific Officer, Stelexis Therapeutics, New York, New York., Little RF; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland., Majeti R; Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Nazha A; Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Nimer SD; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Odenike O; Leukemia Program, Section of Hematology/Oncology, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, Illinois., Padron E; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Platzbecker U; Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany., Della Porta MG; IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University, Milan, Italy., Roboz GJ; Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York., Sallman DA; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Santini V; Myelodysplastic Syndromes Unit, Department of Experimental and Clinical Medicine, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy., Sanz G; Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain., Savona MR; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Sekeres MA; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Stahl M; Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Starczynowski DT; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio., Steensma DP; David Steensma LLC, Cambridge, Massachusetts., Taylor J; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Abdel-Wahab O; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Wei AH; Department of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia., Xie Z; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Xu ML; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut., Hasserjian RP; Department of Pathology, Massachusetts General Hospital Brigham, Boston, Massachusetts., Loghavi S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Sloghavi@mdanderson.org.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Sep 23; Vol. 37 (12), pp. 100615. Date of Electronic Publication: 2024 Sep 23.